One Nucleus appoints Linda Summerton to Board

Immodulon is delighted to announce that Chief Executive Officer, Linda Summerton, has been appointed to the Board of One Nucleus.

One Nucleus is a Cambridge based, not-for-profit membership organisation for international life science and healthcare companies.

Commenting on her appointment Linda said: “Having worked closely with One Nucleus I am very excited about working with the team to support their future objectives. These are challenging times for life sciences and healthcare companies and One Nucleus is extremely well placed to support the sector. I am delighted to have been asked to join the Board and look forward to bringing my experience to the table, to support the team and assist One Nucleus members.”

Jon Green, Chair of One Nucleus commented: “Linda is a great addition to the team. She has a deep understanding of the needs of One Nucleus members, and this coupled with her current interests, particularly as CEO of a growing biotech company make her an ideal Director for One Nucleus”.

One Nucleus was established in 1997 and has grown to have 470 organisations as members. These include a wide range of pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial service providers.

One Nucleus Website